Tag Archives: Allogene

Allogene to Initiate Ph2 ALPHA3 Trial in Mid-2024; Updates from ALLO-316’s TRAVERSE Study Expected in 2024; ALLO-329’s Ph1 Trial in Autoimmune Diseases Set to Start in 2025; Allogene Q4 2023 Earnings Call

On Thursday, March 14, Allogene held its Q4 and FY 2023 earnings call (press release), noting that the start-up activities for the pivotal Ph2 ALPHA3 trial evaluating cema-cel (formerly ALLO-501A; allogeneic CD19 CAR-T) as consolidation therapy in 1L LBCL are ongoing, while the company expects to initiate ALLO-329’s (allogeneic CD19 x CD70 Dagger CAR-T) Ph1 trial in SLE in early 2025.

About The Author

The Celltelligence Team

|
Content Leads & Contributors

The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.

If you receive our email blasts, you already have an account.

Sign UpFREE

You’ll be able to access the full article from your Celltelligence Library after signing up.

JPM 2024 Analysis Day 3: Allogene

On the third day of JPM 2024, Celltelligence covered Allogene’s event (presentation / webcast). Below, Celltelligence provides insights and context to the presentation covering the following topics:

About The Author

The Celltelligence Team

|
Content Leads & Contributors

The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.

If you receive our email blasts, you already have an account.

Sign UpFREE

You’ll be able to access the full article from your Celltelligence Library after signing up.

ALLO-501A’s ALPHA2 Trial Expands to Europe and Australia; EXPAND Study to Open Enrollment in Europe; ALLO-316’s Initial Results Postponed to Early 2024; Allogene’s Q3 2023 Earnings Call Summary

On Thursday, November 2, Allogene held its Q3 2023 earnings call (press release), highlighting the expansion of the Ph1/2 ALPHA2 trial, evaluating ALLO-501A (allogeneic CD19 CAR-T) in ≥3L LBCL, into Europe and Australia and the opening of recruitment in the Ph2 EXPAND trial, studying the use of ALLO-647 (anti-CD52 mAb) as part of the lymphodepletion regimen, in Europe. Additionally, the company delayed the data readout from ALLO-316’s (allogeneic CD70 CAR-T) Ph1 TRAVERSE trial for r/r ccRCC to early 2024 and noted the upcoming presentation of 2 analyses from the ALPHA2 study at ASH 2023. Below, Celltelligence provides insights on Allogene’s difficulties in the onboarding process for the EXPAND study, while discussing the potential development of the Ph3 ALPHA3 trial in earlier line LBCL and the initial interest of the company in non-oncology indications. 

About The Author

The Celltelligence Team

|
Content Leads & Contributors

The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.

If you receive our email blasts, you already have an account.

Sign UpFREE

You’ll be able to access the full article from your Celltelligence Library after signing up.

Why Kite’s New Leader Makes Strategic Sense for Gilead; Allogene’s CMO Pursues Other Opportunities

On May 16, Gilead (Kite) announced the appointment of Cindy Perettie as EVP of Kite (press release), overseeing the cell therapy business. Moreover, on May 18, Replay Bio announced (press release) the appointment of Allogene’s former CMO, Arun Balakumaran, as the company’s new CMO. Below, Celltelligence provides insights on how Perettie’s healthcare experience and background could benefit Gilead’s pursuit of bringing cell therapy to solid tumors.

About The Author

The Celltelligence Team

|
Content Leads & Contributors

The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.

If you receive our email blasts, you already have an account.

Sign UpFREE

You’ll be able to access the full article from your Celltelligence Library after signing up.

ALLO-501’s ALPHA2 Trial Progresses but EXPAND Study Might Experience Difficulties to Enroll; ALLO-316’s AACR Results Highlighted; Allogene Ready for Partnerships to Advance its Programs; Allogene’s Q1 2023 Earnings Call Summary

On Wednesday, May 3, Allogene held its Q1 2023 earnings call (press release / presentation) highlighting the progress made in ALLO-501A’s (allogeneic CD19 CAR-T) ALPHA2 trial while admitting that some clinical trial sites have declined to participate in the EXPAND trial due to its randomized design. Below, Celltelligence provides insights on the consequences of Allogene’s decision to include ALLO-647 (anti-CD52 mAb) in its lymphodepletion regimen for the administration of ALLO-501A and its other cell therapies while discussing potential plans to partner for the development of any of its cell therapy programs.

About The Author

The Celltelligence Team

|
Content Leads & Contributors

The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.

If you receive our email blasts, you already have an account.

Sign UpFREE

You’ll be able to access the full article from your Celltelligence Library after signing up.

Allogene Reports Updated Results from ALLO-316 in Renal Carcinoma; AACR 2023 Analysis 2

AACR 2023 Analysis 2: Allogene reported updated clinical data from its Ph1 TRAVERSE trial evaluating ALLO-316 (allogeneic CD70 CAR-T) in clear cell renal carcinoma (ccRCC). Below, Celltelligence provides insights on the clinical data from ALLO-316 in ccRCC while discussing potential strategies that Allogene could develop to improve ALLO-316 potency in solid tumors.

About The Author

The Celltelligence Team

|
Content Leads & Contributors

The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.

If you receive our email blasts, you already have an account.

Sign UpFREE

You’ll be able to access the full article from your Celltelligence Library after signing up.

ALLO-501A’s Pivotal Trial in ≥3L DLBCL Top Priority for 2023; Clinical Development of BCMA CAR-Ts Postponed Until 2024; Allogene’s Q4 2022 Earnings Call Summary

On Tuesday, February 28, Allogene held its Q4 and FY 2022 (press release) highlighting that their top priority for 2023 is ALLO-501A’s (allogeneic CD19 CAR-T) Ph2 ALPHA2 trial in ≥3L DLBCL, while the clinical development for ALLO-715 (allogeneic BCMA CAR-T) and ALLO-605 (allogeneic BCMA TurboCAR-T) is paused until 2024. Additionally, the company will focus on ALLO-316’s (allogeneic CD70 CAR-T) development in solid tumors with the possibility to expand into liquid tumors. Below, Celltelligence provides insights on Allogene’s decision to focus on ALLO-501A, while discussing ALLO-316’s combination with checkpoint inhibitors in solid tumors and its expansion in hematological tumors.

About The Author

The Celltelligence Team

|
Content Leads & Contributors

The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.

If you receive our email blasts, you already have an account.

Sign UpFREE

You’ll be able to access the full article from your Celltelligence Library after signing up.

Precision BioSciences and 2seventy bio Provide Business Updates for 2023; JPM 2023 Analysis Day 2: Allogene and GSK

A series of cell therapy-related news items have been observed:

About The Author

The Celltelligence Team

|
Content Leads & Contributors

The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.

If you receive our email blasts, you already have an account.

Sign UpFREE

You’ll be able to access the full article from your Celltelligence Library after signing up.

We’re Back! Holiday Recap Ahead of JPM 2023

It’s great to be back in 2023 serving our growing audience! Ahead of JPM Week, there were a few cell therapy-related news items:

About The Author

The Celltelligence Team

|
Content Leads & Contributors

The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.

If you receive our email blasts, you already have an account.

Sign UpFREE

You’ll be able to access the full article from your Celltelligence Library after signing up.

Fate Tx, Adicet Bio, and Allogene Report Clinical Updates from Allogeneic Cell Therapies; ASH 2022 Analysis 1

ASH 2022 Analysis 1: Fate Tx, Adicet Bio, and Allogene presented clinical updates from their allogeneic cell therapies in hematological malignancies. Below, Celltelligence provides insights and context for key selected presentations. The following topics are covered below:

About The Author

The Celltelligence Team

|
Content Leads & Contributors

The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.

If you receive our email blasts, you already have an account.

Sign UpFREE

You’ll be able to access the full article from your Celltelligence Library after signing up.